RevMed’s stunning success; FDA to reclassify peptides; and morenews2026-04-18T10:00:24+00:00April 18th, 2026|Endpoints News|
More pharma dealmaking; FDA’s proposed budget; Takeda ends partnership; and morenews2026-04-11T10:00:58+00:00April 11th, 2026|Endpoints News|
Pharma’s dealmaking tear; Blackstone raises record fund; Xolair energizes allergy research; and more news2026-04-04T10:00:47+00:00April 4th, 2026|Endpoints News|
A week of bolt-on deals; Wave crashes on obesity data; Sanofi partners with TCE startup; and morenews2026-03-28T10:00:36+00:00March 28th, 2026|Endpoints News|
Roche, Nvidia’s ‘AI Factory’; Industry looks to soften MFN impact; Structure’s oral GLP-1 data; and morenews2026-03-21T10:00:30+00:00March 21st, 2026|Endpoints News|
Roche’s breast cancer failure; BioNTech co-founders to depart; Eli Lilly’s quest to stay on top; and more news2026-03-14T10:00:42+00:00March 14th, 2026|Endpoints News|
UniQure’s dispute with FDA; Zealand’s obesity readout; China takes on world’s most expensive medicines; and more news2026-03-07T11:00:32+00:00March 7th, 2026|Endpoints News|
GLP-1 news galore; Top 100 venture investors; Doug Ingram to step down; and morenews2026-02-28T11:00:37+00:00February 28th, 2026|Endpoints News|
Potential Eylea competitor disappoints; FDA to review Moderna’s flu vaccine; Another rare disease rejection; and morenews2026-02-21T11:00:24+00:00February 21st, 2026|Endpoints News|
Moderna vs FDA; Paul Hudson out at Sanofi; Why clinical trials are so costly; and morenews2026-02-14T11:00:17+00:00February 14th, 2026|Endpoints News|
